- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04045678
A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease
A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Chinese PLA General hospital
-
Beijing, China
- Xuanwu Hospital Capital Medical University
-
Shenyang, China
- Shengjing Hospital of China Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient had Parkinson's Disease that meet the clinical diagnostic criteria of the brain bank of the Parkinson's Disease Association of the United Kingdom.
- Patient was Hoehn & Yahr stage ≤3 (excluding stage 0) ;
- Patient was male or female aged 18 to 75 years;
- Patient had a Mini Mental State Examination (MMSE) score of ≥25;
- Patient had a Unified Parkinson's Disease Rating Scale (UPDRS) motor score (Part III) of ≥10 but ≤30 at Screening.
- Patient who signed the informed consent form volunteered to participate in this clinical trial and could cooperate with the prescribed inspections.
Exclusion Criteria:
- Patient had atypical Parkinson's syndrome(s) due to drugs (e.g., metoclopramide, flunarizine), metabolic neurogenetic disorders (e.g., Wilson's disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., progressive supranuclear palsy);
- Patient had a history of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant;
- Patient had dementia, schizophrenia or hallucinations, or clinically significant depression;
- Patient had a lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or presence of suicidal ideation in the past 6 months as indicated by a positive response ("Yes") to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening;
- Patient had a history of orthostatic hypotension with a decrease of ≥20 mmHg in systolic blood pressure (SBP) or ≥10 mmHg in diastolic blood pressure when changing from the supine to the standing position and keeping in the standing position for 3 minutes;
- Patient had received therapy with a dopamine (DA) agonist either concurrently or had done so within 28 days prior to the Screening;
- Patient had received therapy with 1 of the following drugs either concurrently or within 28 days prior to Screening: monoamine oxidase B (MAO-B) inhibitors (e.g., pargyline, selegiline), DA releasing agents (e.g., amphetamine), reserpine, DA-antagonists (e.g., metoclopramide), neuroleptics, or other medications that may interact with DA function;
- Patient was currently (at the time of Screening) receiving central nervous system active therapy (e.g., sedatives, hypnotics, antidepressants, anxiolytics), unless the dose had been stable for at least 28 days prior to Screening Visit and was likely to remain stable for the duration of the study;
- Patient had a current diagnosis of epilepsy, had a history of seizures as an adult within 1 year prior to Screening, had a history of stroke or transient ischemic attack within 3 months prior to Screening;
- Patient had a history of known intolerance/hypersensitivity to non-dopaminergic antiemetics, such as domperidone, ondansetron, tropisetron;
- Patient had clinically significant liver dysfunction (which defined as total bilirubin above the upper limit of normal range, or alanine transferase (ALT) and / or aspartate transferase (AST) 2 times higher than the upper limit of normal range);
- Patient had clinically significant renal insufficiency (serum creatinine >2.0 mg/dL [ >178 μmol/L]);
- Patient had clinically significant cardiac insufficiency and/or had myocardial infarction in the past 12 months;
- Patient had a history of allergic to any medication;
- Heavy smoker, alcoholic, drug addict;
- Female patients who were pregnant or were breastfeeding or were of childbearing potential without adequate contraception; male patients who cannot take adequate contraception during the study;
- Patient who was inappropriate to participant in the study in the judgment of the Investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks. Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks. |
Experimental: LY03003
|
Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks. Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of adverse events
Time Frame: From screening up to day 50
|
Adverse events to evaluate the safety and tolerability of LY03003
|
From screening up to day 50
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of maximum concentration (Tmax) of total LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Maximum concentration in plasma (Cmax) of total LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Area under the concentration-time curve (AUC) from zero up to the last measured concentration [AUC (0-t)] of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Area under the concentration-time curve (AUC) from time zero up to the infinite time [AUC (0-∞)] of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Apparent volume of distribution (Vd) of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Terminal half-life (t1/2) of total LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Total body clearance of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Maximum steady-state drug concentration of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Minimum steady-state drug concentration of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Average steady-state concentration of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Area under the concentration-time curve (AUC) at steady-state concentration of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Fluctuation degree in steady-state concentration of LY03003
Time Frame: From the first injection of stable doses up to day 50
|
From the first injection of stable doses up to day 50
|
|
Change from baseline to the end of the treatment period in the Unified Parkinson's Disease Rating Scale (UPDRS) part (Ⅱ+Ⅲ) Total Score
Time Frame: Screening, baseline, days 29 and day 50
|
The Unified Parkinson´s Disease Rating Scale Part Ⅱ measures "Activities in Daily Living". The total score ranges from 0 (Best score possible) to 52 (Worst score possible). The Unified Parkinson´s Disease Rating Scale Part Ⅲ is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108. |
Screening, baseline, days 29 and day 50
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Dopamine Agonists
- Dopamine Agents
- Rotigotine
Other Study ID Numbers
- LY03003/CT-CHN-103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on LY03003 ( Rotigotine, extended-release microspheres)
-
Luye Pharma Group Ltd.ParexelCompletedParkinson DiseaseChina
-
Luye Pharma Group Ltd.Beijing Bozhiyin T&S Co., Ltd.CompletedParkinson Disease
-
Luye Pharma Group Ltd.Completed
-
Luye Pharma Group Ltd.CompletedParkinson DiseaseUnited States
-
Peking University Third HospitalCompleted
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
Luye Pharma Group Ltd.CompletedParkinson's DiseaseUnited States
-
Ultragenyx Pharmaceutical IncCompletedHereditary Inclusion Body Myopathy (HIBM)United States